The Readout Loud
Podcast autorstwa STAT - Czwartki

Kategorie:
346 Odcinki
-
283: A CRISPR milestone, algorithms amok, & biotech mixology
Opublikowany: 16.11.2023 -
From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?
Opublikowany: 13.11.2023 -
282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
Opublikowany: 9.11.2023 -
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
Opublikowany: 2.11.2023 -
280: ESMO highlights, Roivant's big deal, & biotech VC on the rise
Opublikowany: 26.10.2023 -
279: Live from the 2023 STAT Summit
Opublikowany: 19.10.2023 -
278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
Opublikowany: 12.10.2023 -
277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus
Opublikowany: 5.10.2023 -
276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump
Opublikowany: 28.09.2023 -
275: A thorny ALS debate at the FDA, and the promise of artificial wombs
Opublikowany: 21.09.2023 -
274: Covid’s latest surge, Alnylam at the FDA, & the end of an era
Opublikowany: 14.09.2023 -
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Opublikowany: 7.09.2023 -
272: Vivek's star turn, leaky drug data, & biotech as family business
Opublikowany: 24.08.2023 -
271: Racing for gene therapy, a pioneering approval, & startups in the lurch
Opublikowany: 18.08.2023 -
270: Your guide to Wegovy’s blockbuster heart study
Opublikowany: 10.08.2023 -
269: Biotech layoffs, eye drug drama, & gene therapy milestones
Opublikowany: 3.08.2023 -
268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
Opublikowany: 27.07.2023 -
267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford
Opublikowany: 20.07.2023 -
266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads
Opublikowany: 13.07.2023 -
265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
Opublikowany: 29.06.2023
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.